Mandrake Bio Secures $1.1 Million in Latest Pre-Seed Funding Round

Mandrake Bio secured $1.1 million in its latest Pre-Seed, adding another data point to the Healthcare & Life Sciences funding market.

Mandrake Bio Raises $1.1 million in Funding

Mandrake Bio Raises ₹16 Crore Pre-Seed Round to Advance AI-Powered Gene Editing Platform. Accelerating Agriculture And Genetic Medicine Mandrake Bio’s technology is designed to reduce the time required to develop improved crop varieties through precision gene editing while also supporting the development of therapies for genetic disorders.

Investors Behind the Funding

The round was backed by Activate. Capvizr tracks this investor activity alongside sector momentum, co-investor patterns, and recent comparable raises.

Company Profile and Market Context

Mandrake Bio operates in Healthcare & Life Sciences. Mandrake Bio's financing adds to recent private-market activity.

Strategic Use of Funds

Advance AI-Powered Gene Editing Platform.

Looking Ahead

Mandrake Bio Raises ₹16 Crore Pre-Seed Round to Advance AI-Powered Gene Editing Platform

Source reference: original announcement/article.